Vertex Pharmaceuticals (VRTX) Common Equity (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Common Equity of $19.4 billion for Q1 2026, up 17.37% year-over-year from $16.5 billion in Q1 2025, and up 3.73% quarter-over-quarter from $18.7 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Common Equity (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Common Equity history runs 18 years deep, the most recent figure standing at $19.4 billion for Q1 2026.
- In Q1 2026, Common Equity rose 17.37% year-over-year to $19.4 billion; the TTM figure through Mar 2026 stood at $19.4 billion (up 17.37% YoY), while the FY2025 annual figure was $18.7 billion, up 13.75% from the prior year.
- Common Equity for Q1 2026 stood at $19.4 billion, up from $18.7 billion in the prior quarter.
- The five-year high for Common Equity was $19.4 billion in Q1 2026, with the low at $10.9 billion in Q1 2022.
- The 5-year median for Common Equity is $16.4 billion (2024), against an average of $15.8 billion.
- The sharpest annual moves came in 2022 and 2025: Common Equity soared 37.75% in 2022, then fell 11.05% in 2025.
- Vertex Pharmaceuticals' Common Equity stood at $13.9 billion in 2022, then gained by 26.36% to $17.6 billion in 2023, then dropped by 6.66% to $16.4 billion in 2024, then rose by 13.75% to $18.7 billion in 2025, then climbed by 3.73% to $19.4 billion in 2026.
- Business Quant data shows VRTX's Common Equity at $19.4 billion in Q1 2026, $18.7 billion in Q4 2025, and $17.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.92 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.25 Bn |
| Mar 31, 2026 | 19.36 Bn |
| Dec 31, 2025 | 18.67 Bn |
| Sep 30, 2025 | 17.32 Bn |
| Jun 30, 2025 | 17.18 Bn |
| Mar 31, 2025 | 16.50 Bn |
| Dec 31, 2024 | 16.41 Bn |
| Sep 30, 2024 | 15.63 Bn |
| Jun 30, 2024 | 14.77 Bn |
| Mar 31, 2024 | 18.55 Bn |
| Dec 31, 2023 | 17.58 Bn |
| Sep 30, 2023 | 16.51 Bn |
| Jun 30, 2023 | 15.47 Bn |
| Mar 31, 2023 | 14.43 Bn |
| Dec 31, 2022 | 13.91 Bn |
| Sep 30, 2022 | 13.03 Bn |
| Jun 30, 2022 | 11.93 Bn |
| Mar 31, 2022 | 10.91 Bn |
| Dec 31, 2021 | 10.10 Bn |
| Sep 30, 2021 | 9.53 Bn |